P/E ratio for Standard BioTools (LAB)
P/E ratio as of May 2024 (TTM): -2.42
According to Standard BioTools's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -2.42453. At the end of 2022 the company had a P/E ratio of -0.4795.
P/E ratio history for Standard BioTools from 2011 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -0.4795 | -90.46% |
| 2021 | -5.03 | -38.85% |
| 2020 | -8.22 | 138.55% |
| 2019 | -3.45 | -40.04% |
| 2018 | -5.75 | 85.38% |
| 2017 | -3.10 | 11.57% |
| 2016 | -2.78 | -52.19% |
| 2015 | -5.81 | -67.26% |
| 2014 | -17.8 | -71.25% |
| 2013 | -61.7 | 275.37% |
| 2012 | -16.4 | 186.22% |
| 2011 | -5.75 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.